Jim Cramer on Pfizer Inc. (PFE) CEO Albert Bourla: ‘President-elect Trump Felt That Bourla Was A Hero During COVID’
We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
STAT2d
A biotech legend, pharma CEO, and two Trump admin vets walk into JPM Day 2
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
BioSpace3d
Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
FiercePharma3d
JPM25, Day 1: Pfizer CEO discusses plan to overcome $17B 'LOE wave'
Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...
MM&M2d
These CEOs want to market the next Ozempic. Just don’t call it that
The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.
Pharmaceutical Technology on MSN4d
Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025
CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.
FiercePharma3d
JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales
Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.